Question 1

Does UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS own VKTX stock?

Accepted Answer

Yes. As of its Q2 2026 13F, UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS holds 229,973 shares of VKTX (Viking Therapeutics), worth $9M.

Question 2

How many shares of VKTX does UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS own?

Accepted Answer

As of its Q2 2026 13F, UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS holds 229,973 shares of VKTX (Viking Therapeutics).

Question 3

What is UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS' VKTX position worth?

Accepted Answer

As of its Q2 2026 13F, UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS' VKTX position is worth $9M.

Question 4

Is UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS buying or selling VKTX?

Accepted Answer

In Q2 2026, UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS reduced its VKTX position by 23,921 shares (-9.4%).

Question 5

When did UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS first buy VKTX?

Accepted Answer

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS already held VKTX in its Q4 2018 13F, the earliest on record, and has listed it in 26 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q2 Latest	Decreased	229,973	-9.4%	$9M	0.0%	$39.01	0
2026-Q1	Increased	253,894	+6.6%	$8.3M	0.0%	$32.54	29
2025-Q4	Decreased	238,227	-2.3%	$8.4M	0.0%	$35.18	0
2025-Q3	Decreased	243,766	-52.1%	$6.4M	0.0%	$26.28	0
2025-Q2	Increased	509,094	+8.3%	$13.5M	0.0%	$26.50	30
2025-Q1	Increased	470,028	+1.4%	$11.4M	0.0%	$24.15	28
2024-Q4	Decreased	463,332	-1.9%	$18.6M	0.0%	$40.24	0
2024-Q3	Decreased	472,244	-1.5%	$29.9M	0.0%	$63.31	0